Sibylle Loibl Selected Research

Neoadjuvant Therapy

1/2022	Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial.
1/2022	Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial.
1/2022	Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer.
11/2021	Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness.
10/2021	Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial.
10/2021	AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update.
4/2021	Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial.
1/2021	Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline.
1/2021	Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy.
1/2021	Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sibylle Loibl Research Topics

Disease

235	Breast Neoplasms (Breast Cancer) 04/2022 - 05/2002
111	Neoplasms (Cancer) 01/2022 - 05/2002
34	Triple Negative Breast Neoplasms 06/2022 - 06/2014
24	Pathologic Complete Response 11/2021 - 04/2010
16	Neoplasm Metastasis (Metastasis) 03/2022 - 01/2008
10	Carcinoma (Carcinomatosis) 11/2017 - 05/2002
9	Neutropenia 01/2021 - 07/2010
8	Fatigue 01/2021 - 01/2006
8	Febrile Neutropenia 01/2021 - 04/2010
7	Brain Neoplasms (Brain Tumor) 06/2022 - 02/2009
6	Diarrhea 01/2021 - 04/2010
6	Infections 01/2020 - 11/2011
5	Leukopenia 01/2021 - 07/2015
5	Disease Progression 01/2021 - 07/2008
5	Noninfiltrating Intraductal Carcinoma (DCIS) 11/2020 - 04/2012
5	Residual Neoplasm 01/2019 - 12/2006
4	Hypertension (High Blood Pressure) 01/2020 - 01/2012
4	Exanthema (Rash) 01/2019 - 08/2009
4	Ovarian Neoplasms (Ovarian Cancer) 01/2018 - 12/2006
3	Vomiting 01/2021 - 01/2020
3	Nausea 01/2021 - 01/2020
3	Anemia 01/2021 - 01/2006
3	Amenorrhea 01/2021 - 06/2011
3	Inflammatory Breast Neoplasms 01/2021 - 01/2010
3	Cardiotoxicity 12/2020 - 01/2008
3	Circulating Neoplastic Cells 01/2018 - 05/2010
3	Thrombocytopenia (Thrombopenia) 07/2015 - 07/2013

Drug/Important Bio-Agent (IBA)

55	Hormones (Hormone)IBA 03/2022 - 01/2006
39	Trastuzumab (Herceptin)FDA Link 01/2022 - 02/2009
36	taxaneIBA 10/2021 - 01/2008
33	AnthracyclinesIBA 01/2021 - 01/2008
29	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022 - 01/2006
27	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2008
27	human ERBB2 proteinIBA 01/2021 - 01/2009
20	Epirubicin (Ellence)FDA LinkGeneric 01/2022 - 11/2007
20	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 07/2008
17	ErbB Receptors (EGF Receptor)IBA 01/2022 - 10/2002
17	Estrogen ReceptorsIBA 01/2022 - 02/2007
16	Docetaxel (Taxotere)FDA Link 01/2020 - 01/2006
15	Capecitabine (Xeloda)FDA Link 01/2022 - 04/2008
14	Proteins (Proteins, Gene)FDA Link 10/2021 - 10/2002
13	Phenobarbital (Luminal)FDA Link 01/2022 - 11/2010
13	Carboplatin (JM8)FDA LinkGeneric 01/2022 - 07/2008
12	Bevacizumab (Avastin)FDA Link 01/2020 - 01/2011
11	Fulvestrant (Faslodex)FDA Link 01/2022 - 03/2015
11	Biological ProductsIBA 12/2020 - 02/2007
10	palbociclibIBA 01/2022 - 07/2015
10	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 01/2006
9	130-nm albumin-bound paclitaxelIBA 01/2022 - 07/2010
9	Lapatinib (GW572016)FDA Link 08/2019 - 01/2008
8	Messenger RNA (mRNA)IBA 01/2021 - 02/2013
7	Pharmaceutical PreparationsIBA 01/2020 - 01/2008
7	Taxoids (Taxanes)IBA 02/2016 - 01/2008
6	Epidermal Growth Factor (EGF)IBA 07/2020 - 10/2002
5	Poly(ADP-ribose) Polymerase InhibitorsIBA 04/2022 - 06/2011
5	pertuzumabIBA 01/2022 - 07/2015
5	ParaffinIBA 07/2020 - 01/2010
5	Formaldehyde (Formol)FDA Link 07/2020 - 01/2010
5	Fluorouracil (Carac)FDA LinkGeneric 01/2020 - 08/2003
5	Gonadotropin-Releasing Hormone (GnRH)FDA Link 01/2018 - 08/2005
5	Goserelin (Zoladex)FDA Link 01/2017 - 08/2005
4	Immune Checkpoint InhibitorsIBA 12/2021 - 10/2016
4	Progesterone Receptors (Progesterone Receptor)IBA 09/2021 - 01/2009
4	Tamoxifen FDA LinkGeneric 01/2019 - 08/2005
4	Monoclonal AntibodiesIBA 06/2018 - 04/2003
4	Bendamustine Hydrochloride FDA Link 12/2011 - 01/2008
4	Nitric Oxide (Nitrogen Monoxide)FDA Link 07/2008 - 09/2002
3	sacituzumab govitecanIBA 06/2022 - 01/2021
3	Cyclin-Dependent Kinase 4IBA 01/2022 - 01/2017
3	liposomal doxorubicin (Doxil)FDA Link 01/2022 - 01/2019
3	Letrozole (Femara)FDA LinkGeneric 01/2021 - 03/2015
3	Vinorelbine (Navelbine)FDA LinkGeneric 01/2021 - 04/2008
3	Immunoconjugates (Immunoconjugate)IBA 01/2021 - 01/2019
3	Estrogens (Estrogen)FDA Link 01/2021 - 01/2006
3	Aromatase InhibitorsIBA 11/2020 - 01/2016
3	tucatinibIBA 10/2020 - 06/2018
3	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 07/2020 - 10/2014
3	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 03/2016
3	Ado-Trastuzumab EmtansineIBA 01/2020 - 01/2019
3	Cytotoxins (Cytolysins)IBA 01/2019 - 01/2008
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2015 - 01/2011
3	Methotrexate (Mexate)FDA LinkGeneric 10/2015 - 11/2007
3	LipidsIBA 04/2014 - 05/2011
2	durvalumabIBA 01/2022 - 01/2021
2	PlatinumIBA 11/2021 - 06/2014
2	veliparibIBA 11/2021 - 01/2018
2	RNA (Ribonucleic Acid)IBA 11/2021 - 11/2021
2	Poly Adenosine Diphosphate RiboseIBA 01/2021 - 06/2011
2	eribulin FDA Link 01/2021 - 01/2019
2	neratinibIBA 01/2021 - 06/2018
2	Progesterone FDA LinkGeneric 01/2021 - 01/2019

Therapy/Procedure

104	Neoadjuvant Therapy 01/2022 - 01/2006
85	Therapeutics 06/2022 - 10/2002
78	Drug Therapy (Chemotherapy) 04/2022 - 08/2005
13	Adjuvant Chemotherapy 06/2022 - 01/2008
5	Immunotherapy 04/2022 - 11/2017
5	Radiotherapy 10/2021 - 02/2009
5	Aftercare (After-Treatment) 11/2020 - 10/2011
4	Combination Drug Therapy (Combination Chemotherapy) 01/2021 - 01/2010
2	Operative Surgical Procedures 10/2021 - 11/2006